Chardan Capital assumed coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research note published on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the company. 92 Resources reiterated a reiterates rating on […]
Chardan Capital started coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock. A number of other analysts have also weighed in on FDMT. HC Wainwright restated a “buy” rating and […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating)’s share price dropped 5.2% during trading on Wednesday . The stock traded as low as $21.99 and last traded at $22.06. Approximately 128,644 shares were traded during trading, a decline of 73% from the average daily volume of 480,035 shares. The stock had previously closed at $23.26. […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) shares traded up 7.5% on Friday after Bank of America raised their price target on the stock from $28.00 to $33.00. The stock traded as high as $21.29 and last traded at $20.99. 73,528 shares were traded during trading, a decline of 85% from the average session […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 2,840,000 shares, a drop of 10.1% from the April 15th total of 3,160,000 shares. Based on an average trading volume of 510,400 shares, the days-to-cover ratio […]